



**Date: January 14, 2025**

**To**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

Dear Sir/ Madam,

**Subject: Certificate for the quarter ended December 31, 2024 pursuant to the SEBI Master Circular for issue and listing of Non-convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 22 May 2024 (“SEBI Master Circular”)**

Pursuant to SEBI Master Circular it is hereby certify that:

1. The proceeds of the below mentioned Commercial Paper(s) issued by the Company and outstanding as on the quarter ended December 31, 2024 were used for the purpose of part financing the acquisition of securities of Bharat Serums and Vaccines Limited as mentioned in the disclosure document.

Sr. No.	ISIN No.	Amount (Rs. in Crore)	Units	Maturity date
1	INE634S14021	3,000	60,000	16-01-2025
2	INE634S14013	500	10,000	17-04-2025
3	INE634S14039	1,500	30,000	17-10-2025

2. The other listing conditions as specified under Chapter XVII of the SEBI Master Circular and amendments thereof have been adequately adhered to.

The information in the above intimation is also being uploaded on the website of the Company at [www.mankindpharma.com](http://www.mankindpharma.com).

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Ashutosh Dhawan**  
**Global Chief Financial Officer**